Literature DB >> 31381953

Diverse mechanisms of PARP inhibitor resistance in ovarian cancer.

Matthew John Wakefield1, Ksenija Nesic2, Olga Kondrashova3, Clare L Scott4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31381953     DOI： 10.1016/j.bbcan.2019.08.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN： 0304-419X            Impact factor:   10.680


× No keyword cloud information.
  4 in total

1.  The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.

Authors:  Saya L Jacob; Lesli A Kiedrowski; Young K Chae
Journal:  Heliyon       Date:  2020-05-08

Review 2.  PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.

Authors:  Elizabeth K Lee; Ursula A Matulonis
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

3.  The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.

Authors:  Elaine Sanij; Richard B Pearson; Keefe T Chan; Shunfei Yan; Jiachen Xuan; Natalie Brajanovski; Madeleine R C Tancock; Piyush B Madhamshettiwar; Kaylene J Simpson; Sarah Ellis; Jian Kang; Carleen Cullinane; Karen E Sheppard; Katherine M Hannan; Ross D Hannan
Journal:  Br J Cancer       Date:  2020-11-11       Impact factor: 7.640

Review 4.  Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.

Authors:  Nirashaa T Bound; Cassandra J Vandenberg; Apriliana E R Kartikasari; Magdalena Plebanski; Clare L Scott
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.